Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

BrainCool

0.58 SEK

+9.23 %

Less than 1K followers

BRAIN

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
+9.23 %
+5.29 %
-33.06 %
-64.13 %
-56.14 %
-56.59 %
-59.91 %
-86.43 %
-67.17 %

BrainCool operates in the medical technology sector. The company develops products for medical cooling of the brain. The technology is developed as cooling pads that are applied to different parts of the patient's body, where the system controls body temperature. The products are used in the treatment of various serious conditions including stroke, cardiac arrest, as well as concussion and migraine. BrainCool was founded in 2010 and is headquartered in Lund.

Read more
Market cap
195.96M SEK
Turnover
119.08K SEK
Revenue
39.96M
EBIT %
-105.58 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
11/2
2026

Annual report '25

All
Webcasts
Press releases
ShowingAll content types
Regulatory press releaseyesterday

BrainCool utser Anna Lindström till ny vd

BrainCool
Regulatory press releaseyesterday

BrainCool appoints Anna Lindström as new CEO

BrainCool
Regulatory press release12/12/2025, 7:00 AM

BrainCool erhåller ett bidragstillskott från EU på cirka 6 miljoner SEK för COTTIS 2-studien och förstärker sitt kliniska team

BrainCool

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release12/12/2025, 7:00 AM

BrainCool receives supplementary EU grant of approximately SEK 6 million for the COTTIS 2 study and strengthens its clinical team

BrainCool
Press release12/11/2025, 10:41 AM

BioStock: BrainCool växlar upp med säkerställd emission – siktar på svarta siffror

BrainCool
Press release12/9/2025, 9:03 AM

BioStock: BrainCool pratar emission och vägen framåt

BrainCool
Regulatory press release12/9/2025, 7:00 AM

BrainCool ansöker om MDR-godkännande för BrainCool System

BrainCool
Press release12/8/2025, 6:40 AM

BioStock: BioStock Investor Pitch: BrainCool

BrainCool
Press release12/4/2025, 10:01 AM

BioStock: BrainCools vd kommenterar tillväxt och emission

BrainCool
Regulatory press release12/1/2025, 2:53 PM

BrainCool publishes information document regarding rights issue

BrainCool
Regulatory press release12/1/2025, 2:53 PM

BrainCool offentliggör informationsdokument avseende företrädesemission

BrainCool
Regulatory press release11/26/2025, 11:35 AM

Kommuniké från extra bolagsstämma i BrainCool

BrainCool
Regulatory press release11/26/2025, 11:35 AM

Communiqué from extraordinary general meeting in BrainCool

BrainCool
Regulatory press release10/29/2025, 7:00 AM

PRINCESS 2 med BrainCools produkt RhinoChill® System uppmärksammad vid möte för European Resuscitation Guidelines

BrainCool
Regulatory press release10/27/2025, 7:00 AM

BrainCool stärks av uppdaterade riktlinjer i USA för medicinsk precisionskylning vid plötsligt hjärtstopp

BrainCool
Regulatory press release10/24/2025, 6:40 AM

BrainCool AB (publ) - Delårsrapport Q3 2025

BrainCool
Regulatory press release10/24/2025, 6:05 AM

KALLELSE TILL EXTRA BOLAGSSTÄMMA I BRAINCOOL AB (PUBL)

BrainCool
Regulatory press release10/24/2025, 6:05 AM

NOTICE OF EXTRA GENERAL MEETING IN BRAINCOOL AB (PUBL)

BrainCool
Regulatory press release10/24/2025, 6:00 AM

BrainCool genomför en företrädesemission om cirka 42 MSEK som fullt ut omfattas av teckningsåtaganden och tidigarelägger publicering av Q3-rapport

BrainCool
Regulatory press release10/24/2025, 6:00 AM

BrainCool carries out a rights issue of approximately SEK 42 million which is fully covered by subscription undertakings and advances publication of Q3 report

BrainCool
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.